Halozyme Therapeutics Surges on 86.74% Volume Spike to $360M, 329th Market Activity as Royalty Revenue Drives 41% EBITDA Jump

Halozyme Therapeutics (NASDAQ: HALO) closed August 6, 2025, up 2.48% as trading volume surged 86.74% to $360 million, ranking 329th in market activity. The biopharma firm reported Q2 2025 revenue of $326 million, a 41% year-over-year increase driven by $206 million in royalty income from subcutaneous therapies enabled by its ENHANZE platform. Adjusted EBITDA rose 65% to $226 million, reflecting the company’s asset-light business model with no manufacturing or clinical costs.

Management raised 2025 guidance to $1.275 billion–$1.355 billion in revenue, with royalty growth projected at 44%–51% year-over-year. This upgrade follows 14 growth catalysts, including new partnerships and auto-injector development. ENHANZE’s intellectual property (IP) and first-mover advantage in subcutaneous drug delivery are seen as key drivers of long-term royalty durability, though ongoing litigation with Merck over 15 patents and $977 million in net debt remain risks.

The strategy of purchasing the top 500 stocks by daily trading volume and holding for one day returned 166.71% from 2022 to the present, outperforming the benchmark by 137.53%. This highlights liquidity concentration’s role in short-term performance, particularly in volatile markets where high-volume stocks often exhibit stronger price momentum due to increased trading activity and demand.